| __timestamp | Ionis Pharmaceuticals, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 20140000 | 5078000000 |
| Thursday, January 1, 2015 | 37173000 | 4717000000 |
| Friday, January 1, 2016 | 48616000 | 5096000000 |
| Sunday, January 1, 2017 | 108488000 | 4986000000 |
| Monday, January 1, 2018 | 244622000 | 4214000000 |
| Tuesday, January 1, 2019 | 287000000 | 3806000000 |
| Wednesday, January 1, 2020 | 354000000 | 3671000000 |
| Friday, January 1, 2021 | 186000000 | 3528000000 |
| Saturday, January 1, 2022 | 151000000 | 3445000000 |
| Sunday, January 1, 2023 | 232600000 | 3498000000 |
| Monday, January 1, 2024 | 267474000 | 3702000000 |
Unlocking the unknown
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This analysis compares the SG&A expenses of Teva Pharmaceutical Industries Limited and Ionis Pharmaceuticals, Inc. from 2014 to 2023.
Teva, a global leader in generic medicines, consistently reported higher SG&A expenses, peaking in 2016 with nearly 5.1 billion USD. However, a downward trend is evident, with a 32% reduction by 2023. This reflects Teva's strategic cost-cutting measures amidst industry challenges.
Conversely, Ionis, a pioneer in RNA-targeted therapeutics, saw its SG&A expenses grow by over 1,000% from 2014 to 2020, highlighting its aggressive expansion and investment in innovation. Despite a slight dip in 2021, Ionis's expenses rebounded by 2023, indicating renewed growth strategies.
This financial narrative underscores the dynamic strategies of these pharmaceutical titans in navigating market complexities.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Intra-Cellular Therapies, Inc.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Dr. Reddy's Laboratories Limited
SG&A Efficiency Analysis: Comparing Teva Pharmaceutical Industries Limited and Ascendis Pharma A/S
Teva Pharmaceutical Industries Limited vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated
Intra-Cellular Therapies, Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Sarepta Therapeutics, Inc. and Ionis Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Ionis Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc and Ionis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Ionis Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Mesoblast Limited